文献速递多重用药认知障碍与谵妄老年综合评估

多重用药与社区老年人轻度认知障碍:DO-HEALTH 三年观察分析

Polypharmacy and Mild Cognitive Impairment in Older Adults: A 3-year Study of DO-HEALTH.
PubMed 文献 · J Am Med Dir Assoc · 2025-04-19

该研究基于 DO-HEALTH 试验,纳入 2153 名≥70 岁认知功能良好的社区居住老年人,分析基线多重用药(≥5 种药物)与轻度认知障碍(MCI,MoCA<26)在基线和 3 年内的关联。结果显示,多重用药者基线 MCI 患病率更高(MoCA<26:53.5% vs 46.5%),纵向分析中多重用药与 MCI 风险升高相关,但控制心理健康和共病后关联减弱且不显著。

要点

  • 多重用药(≥5种药物)与社区老年人基线及3年内MCI风险升高相关。
  • 基线MCI患病率在多重用药者中更高(MoCA<26:53.5% vs 46.5%)。
  • 控制心理健康和共病后,多重用药与MCI的关联减弱且不显著。

核心结论

  • 多重用药与社区老年人基线及3年内MCI风险升高相关,但控制心理健康和共病后关联减弱且不显著。

研究设计与样本

  • DO-HEALTH试验的观察性分析,纳入2153名≥70岁认知功能良好且无重大疾病的社区居住老年人。

主要发现

  • 基线MCI患病率在多重用药者中更高(MoCA<26:53.5% vs 46.5%;MoCA<24:34.9% vs 17.2%)。
  • 最小调整模型中,多重用药与基线MCI风险升高相关(MoCA<26:OR 1.32,95%CI 1.05-1.66;MoCA<24:OR 1.37,95%CI 1.06-1.79)。
  • 3年随访中,多重用药与MCI风险升高相关(MoCA<26:OR 1.28,95%CI 1.08-1.52;MoCA<24:OR 1.33,95%CI 1.07-1.65)。
  • 控制心理健康和共病后,上述关联减弱且不显著。

关键数值与推荐

  • 多重用药定义为基线使用≥5种药物。
  • MCI定义为MoCA评分<26,敏感性分析采用MoCA<24。

临床怎么用

  • 对多重用药的社区老年人应关注认知功能筛查,同时评估心理健康和共病情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between polypharmacy and mild cognitive impairment (MCI) at baseline and over 3 years in community-dwelling older adults. DESIGN: Observational analysis of the DO-HEALTH trial. SETTING AND PARTICIPANTS: Community-dwelling adults aged ≥70 years with good cognitive function and without major diseases at baseline. METHODS: Main exposure was polypharmacy at baseline (≥5 medications). The outcome was MCI (Montreal Cognitive Assessment [MoCA] score <26), assessed at baseline and years 1, 2, and 3. Logistic regression and generalized estimating equations (GEEs) for repeated binary outcomes were used for the cross-sectional and longitudinal analysis, respectively. Minimally adjusted models included age, sex, prior fall, study site, body mass index, and education. Fully adjusted models additionally adjusted for mental health and multimorbidity. GEE models also accounted for time and DO-HEALTH treatment effects. Sensitivity analysis used a stricter MCI definition (MoCA < 24). RESULTS: A total of 2153 participants completed MoCA at baseline. Baseline MCI prevalence was higher in participants with polypharmacy compared with those with no polypharmacy (MCI < 26: 53.5% vs 46.5%; MCI < 24: 34.9% vs 17.2%). Polypharmacy was associated with greater MCI odds at baseline in the minimally adjusted models (MoCA < 26: odds ratio [OR], 1.32; 95% CI, 1.05-1.66; MoCA < 24: OR, 1.37; 95% CI, 1.06-1.79). Over 3 years, polypharmacy was associated with increased MCI odds in the minimally adjusted models (MoCA < 26: OR, 1.28; 95% CI, 1.08-1.52; MoCA < 24: OR, 1.33; 95% CI, 1.07-1.65). Notably, these associations were somewhat attenuated and nonsignificant after controlling for mental health and multimorbidity. CONCLUSION AND IMPLICATIONS: Our findings suggest that MCI is more prevalent in older adults with polypharmacy compared with those without polypharmacy. Although polypharmacy was associated with MCI at baseline and over 3 years, these associations were attenuated by mental health and multimorbidity, suggesting that mental health and multimorbidity contribute to both polypharmacy and MCI.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. de Godoi Rezende Costa Molino C, Baumann K, Gaengler S, et al. Polypharmacy and Mild Cognitive Impairment in Older Adults: A 3-year Study of DO-HEALTH. J Am Med Dir Assoc. 2025. PMID: 40199365. doi:10.1016/j.jamda.2025.105586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。